LAUSR

To assess the incidence and vulnerability of rheumatology patients to COVID-19 infection in early stages of pandemic. Self completed questionnaire was posted to patients. Patients diagnosed with rheumatic diseases were categorised as people at high risk of infection with COVID-19 (pharmacologically immunosuppressed) and with possible worsening outcomes than the general population. This study was a self-completed questionnaire which was sent to all patients registered under a National Health Services specialist rheumatology department in the UK, between May 2020 and May 2021. A total of 610 responses were received and data was analysed statistically. The aim from this survey was to assess COVID19 infection prevalence amongst rheumatology patients under the care of this department, and to examine the profiles of patients with reported COVID-19 infection, their comorbidities, rheumatoid-related medications and infection severity and outcome. Of 610 responders diagnosed with rheumatoid diseases, 12 patients (1.96%) received a diagnosis of COVID-19 based on their clinical presentation. However, when patients undertaken a Polymerase Chain Reaction test, only 2 patients (16.6%) returned positive results. In both the COVID-19 and non-COVID groups 60% were shielding (n = 361). In our sample infection rate was around 30 times (1 in 50 rheumatoid patients, 2% in the sample population) the prevailing rate for the general population in the region (75 in 100,000, 0.075% in the general population). Negative testing did not preclude the presence of disease, but this may reflect poor efficacy and reliability of testing in the early days of the pandemic. The sample means and SD+/- were 63.96/13.23 for age and 27.76/5.79 for BMI. Sample population characteristics presented in Table 1. This patient group were more vulnerable to COVID-19 infection compared to the general population but appear not to be at greater risk of severe disease. Disclosure A. El Rashid: None. R. Patil: None. L. Burgress: None. P. Ball: None. H. Morrissey: None. A. Askari: None.